Haemoglobin synthesis following injection of iron-poly (sorbitol-gluconic acid) complex, Ferastral.
Ferastral, a new iron-poly (sorbitol-gluconic acid) complex for parenteral use has been given to 22 patients with iron deficiency anaemia. The patients were divided in two groups. Group I received a suboptimal dose of Ferastral iron corresponding to 90% of the iron calculated to normalize the haemoglobin value. Increases in total haemoglobin and also blood losses were measured. The availability of the injected iron for haemoglobin synthesis ranged from 63% to 111%. Group II received an amount of Ferastral-iron calculated to be necessary for normalization of the haemoglobin plus an additional 500 mg of Ferastral-iron. In this group the haemoglobin increase was rapid. In 7 weeks 10 out of 14 patients had reached a normal haemoglobin level.
D000328:Adult; D000747:Anemia, Hypochromic / Q000188:drug therapy*; D001853:Bone Marrow / Q000378:metabolism; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D005942:Gluconates / Q000627:therapeutic use; D006454:Hemoglobins / Q000096:biosynthesis*; D006801:Humans; D007501:Iron / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013012:Sorbitol / Q000627:therapeutic use
D004338:Drug Combinations; D005942:Gluconates; D006454:Hemoglobins; D013012:Sorbitol; D007501:Iron